Diamond Biofund Inc is a Taiwan-based company primarily engaged in the venture capital and general investment industries. The Company focuses on investments in the biotechnology and medical fields. Main investment areas include new drug research and development, high-end medical devices, innovative medical service technologies or models, medical access, and agricultural biotechnology. The Company's investments are primarily in the domestic sector.

Employees

Sector

Investment Management & Fund Operators

More about the company

Quotes

Date	Price	Change	Volume
15/09/26	NT$15.10	+0.33%	530,157
14/09/26	NT$15.05	+2.03%	746,786
11/09/26	NT$14.75	-1.67%	788,528
10/09/26	NT$15.00	-0.66%	574,748
09/09/26	NT$15.10	-0.98%	730,811

End-of-day quote Taiwan S.E.

More quotes

End-of-day quote Taiwan S.E. 15/09/2026			5-day change	1st Jan Change
15.10 ^TWD	+0.33%		-0.98%	-8.48%

08-11	Diamond Biofund Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-05	Diamond Biofund Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	12.89B 404M 350M 331M 300M 562M 38.75B 566M 3.95B 1.52B 19.65B 1.52B 1.48B 62.66B	P/E 2024	-11x	P/E 2025	-12x
Enterprise Value	9.09B 285M 247M 233M 211M 397M 27.33B 399M 2.78B 1.07B 13.86B 1.07B 1.05B 44.19B	EV / Sales 2024	-10.2x	EV / Sales 2025	-9.56x
Free-Float	16.24%	Yield 2024 *	-	Yield 2025	-

08-11	Diamond Biofund Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-05	Diamond Biofund Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-12	Diamond Biofund Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-22	Diamond Biofund Inc. Announces Financial Officer Changes, Effective December 22, 2025	CI
11-10	Diamond Biofund Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
07/08/25	Diamond Biofund Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
09/05/25	Diamond Biofund Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
26/02/25	Diamond Biofund Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
10/12/24	Diamond Biofund Logs Negative Revenue for Three Straight Months	MT
11/11/24	Diamond Biofund Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
09/08/24	Diamond Biofund Incurs Over NT$941 Million Loss in H1	MT
09/08/24	Diamond Biofund Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
08/08/24	Stemcyte International, Inc. announced that it expects to receive $19.05 million in funding from Diamond Biofund Inc.	CI

1 day	+0.33%
1 week	-0.98%
Current month	-4.73%
1 month	-8.48%
3 months	-5.62%
6 months	+1.34%
Current year	-8.48%

Diamond Biofund Inc. Share Price

Stocks

6901

TW0006901002

Investment Management & Fund Operators

Valuation: Diamond Biofund Inc.

Chart: Diamond Biofund Inc.

Latest news: Diamond Biofund Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Diamond Biofund Inc.

Other Investment Management & Fund Operators

Financials

Company Profile

Quotes

1 week	14.5	15.15
1 month	14.5	17.55
Current year	12.05	22.4
1 year	12.05	22.4
3 years	12.05	68.4
5 years	12.05	200.19
10 years	12.05	200.19

Manager	Title	Age	Since
Shu Ling Cheng CEO	Chief Executive Officer	-	-
Yuan Ting Wu DFI	Director of Finance/CFO	-	-

Director	Title	Age	Since
Kung Ming Lu CHM	Chairman	-	-
Tsu Te Li BRD	Director/Board Member	-	-
Wan Chun Chen BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DIAMOND BIOFUND INC.	+0.33%	-0.98%	-24.31%	-77.40%	404M
BLACKROCK, INC.	-0.65%	-3.35%	-5.06%	+51.80%	164B
UBS GROUP AG	-3.39%	-6.98%	+26.39%	+78.89%	156B
BANK OF NEW YORK MELLON CORPORATION (THE)	-1.90%	-5.02%	+45.34%	+242.11%	105B
BROOKFIELD CORPORATION	-1.20%	-4.67%	-18.92%	+58.86%	82.86B
BROOKFIELD ASSET MANAGEMENT LTD.	-1.70%	-5.38%	-19.92%	+30.50%	73.21B
STATE STREET CORPORATION	-1.61%	-3.52%	+65.12%	+157.66%	50.86B
AMERIPRISE FINANCIAL, INC.	+0.14%	+0.48%	+14.70%	+61.14%	49.41B
3I GROUP PLC	-1.22%	-6.81%	-32.70%	+24.71%	35.12B
NORTHERN TRUST CORPORATION	-1.63%	-3.32%	+37.22%	+145.79%	32.7B
Average	-1.28%	-3.78%	+8.78%	+77.41%	74.99B
Weighted average by Cap.	-1.64%	-4.01%	+12.17%	+93.34%

	2024	2025
Net sales	-2.23B -69.87M -60.52M -57.23M -51.81M -97.24M -6.7B -97.97M -683M -263M -3.4B -262M -257M -10.84B	-1.07B -33.64M -29.14M -27.56M -24.95M -46.82M -3.23B -47.18M -329M -127M -1.64B -126M -124M -5.22B
Net income	-2.52B -78.94M -68.37M -64.65M -58.53M -110M -7.57B -111M -772M -297M -3.84B -297M -290M -12.24B	-1.17B -36.83M -31.9M -30.16M -27.31M -51.25M -3.53B -51.64M -360M -138M -1.79B -138M -135M -5.71B
Net Debt	-5.01B -157M -136M -129M -117M -219M -15.07B -220M -1.54B -591M -7.64B -590M -577M -24.37B	-3.8B -119M -103M -97.5M -88.27M -166M -11.42B -167M -1.16B -448M -5.79B -447M -437M -18.46B